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Introduction:  India  accounts  for  an  estimated  457,000–884,000  hospitalizations  and  2  million  outpa-
tient  visits  for  diarrhea.  In  spite  of  the  huge  burden  of  rotavirus  (RV)  disease,  RV  vaccines  have  not
been introduced  in  national  immunization  programme  of  India.  Therefore,  continuous  surveillance  for
prevalence  and  monitoring  of  the  circulating  genotypes  is  needed  to assess  the  disease  burden  prior  to
introduction  of  vaccines  in  this  region.
Methods:  During  January  2011  through  December  2013, 830 and  1000  stool  samples  were  collected  from
hospitalized  and  out-patient  department  (OPD)  patients,  respectively,  in  two hospitals  in Kolkata,  Eastern
India.  After  primary  screening,  the G-P  typing  was  done  by multiplex  semi-nested  PCR  using  type  speciﬁc
primers  followed  by  sequencing.  Phylogenetic  analysis  for the  VP7  gene  of  25  representative  strains  was
done.
Results:  Among  hospitalized  and  OPD  patients,  53.4%  and  47.5%  cases  were  positive  for  rotaviruses,  respec-
tively.  Unlike  previous  studies  where  G1  was  predominant,  in  hospitalized  cases  G9  rotavirus  strains  were
most prevalent  (40%),  followed  by  G2  (39.6%)  whereas  G1  and  G12  occurred  at  16.4%  and  5.6%  frequency.
In  OPD  cases,  the  most  prevalent  strain  was  G2 (40.3%),  followed  by G1,  G9  and  G12  at  25.5%,  22.8%,  9.3%,
respectively.  Phylogenetically  the  G1,  G2  and  G9  strains  from  Kolkata  did  not  cluster  with  corresponding
genotypes  of Rotarix,  RotaTeq  and  Rotavac  (116E)  vaccine  strains.
Conclusion:  The  study  highlights  the  high  prevalence  of  RV  in  children  with  gastroenteritis  in Kolkata.
The  circulating  genotypes  have  changed  over  the time  with  predominance  of G9  and  G2 strains  during
2011-2013.  The  current  G2,  G9  and  G1  Kolkata  strains  shared  low  amino  acid  homologies  with  current
vaccine  strains.  Although  there  is  substantial  evidence  for cross  protection  of vaccines  against  a variety
of strains,  still  the  strain  variation  should  be monitored  post vaccine  introduction  to  determine  if it  has
any  impact  on  vaccine  effectiveness.
d  by © 2014  Publishe
. Introduction
Rotavirus is the leading cause of diarrhea and is associated
ith 453,000 childhood deaths globally [2]. India accounts for an
stimated 457,000–884,000 hospitalizations, 2 million outpatient
isits for diarrhea, resulting in huge medical and health care costs
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264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC Elsevier  Ltd.  This is an  open  access  article  under  the  CC  BY-NC-ND  license
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[1]. Annually more than 334,000 deaths occurring in Indian children
are attributed to diarrheal disease, of which about 98,000 deaths are
due to rotavirus alone [3].
Group A rotavirus (RVA) is a double stranded RNA virus consist-
ing of 11 segments. Two  outer capsid proteins, VP7 (G genotype)
and VP4 (P genotype), independently elicit a serotype-speciﬁc neu-
tralizing immune responses that may  play an important role in
protection against recurrent infections [4]. These viruses are genet-
ically diverse, and RVA VP4 and VP7 encoding genes have been
classiﬁed into atleast 27 G genotypes (G1–27) and 37 P genotypes
(P[1]–[37]), respectively, based on differences in their nucleotide
sequences [5,6]. The segmented nature of rotavirus genome
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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rovides the mechanism for the generation of genetic diversity
y the process of genetic reassortment, which may  occur during
o-infections of circulating human and animal strains [7–9].
Two rotavirus vaccines namely Rotarix® (RV1; monovalent
1P[8]; GlaxoSmithKline Biologicals, Rixensart, Belgium) and
otaTeq® (RV5; pentavalent G1, G2, G3, G4,P[8]; Merck Vaccines,
hitehouse Station, NJ, USA) are commercially available since
006. Recently, another oral live attenuated vaccine candidate has
een evaluated in phase III studies in India, and is derived from
 G9P [11] human bovine reassortant strain 116E [10–12]. Large
cale vaccine trials with Rotarix and RotaTeq have shown high efﬁ-
acy in developed countries of Europe, Australia and USA though
fﬁcacy is lower (39–72%) in low income countries of Asia and
frica [13–15]. In spite of lower efﬁcacy, these vaccines reduce
 greater number of severe rotavirus gastroenteritis events in
eveloping countries because of the great background rate of dis-
ase, resulting in the WHO’s recommendations for introduction
f RV vaccines in national immunization programs worldwide in
009 [16]. However, RV vaccines have still not been introduced in
ational immunization programme of most South Asian and African
ountries, for several reasons including lack of disease burden data
nd economic feasibility.
During the past decade, several surveillance studies in hos-
italized children have reported prevalence and strain diversity
f RVA across India [18–22]. A multicenter hospital based study
2005–2009) in India, including Eastern India, estimated 40% hos-
italization rates due to rotavirus [17,21]. The predominant strain
irculating during 2005–2009 was G1P[8], followed by G2P[4]. G3,
4, G9 and G12 strains were observed at lower frequency (<10%)
17,21,22].Most surveillance studies done in India were focussed on
hildren hospitalized with acute gastroenteritis; however, the pro-
ortion of RVAs in cases of milder diarrhea and often reporting to
utpatient departments (OPD) (some or no dehydration) remains
ig. 1. Temporal distribution of rotavirus-positive cases in Kolkata during January 2011 t
nd  (B) OPD patients (<5 years) with mild diarrhea. Lines represent month wise distribut2S (2014) A20–A28 A21
largely unknown. The aim of this study was  to analyse prevalence of
rotavirus among children either hospitalized with severe diarrhea
or seeking treatment for milder diarrhea in OPD (during January
2011–December 2013) and to compare the rotavirus genotypes
among the two sets of patients.
2. Methods
2.1. Sample collection and screening
The study was conducted from January 2011 through December
2013 in ID-BG Hospital and B.C. Roy Memorial Hospital for Chil-
dren in Kolkata, Eastern India. Stool samples of every ﬁfth admitted
patient (≤5 years of age) with acute watery diarrhea, vomiting
and abdominal pain, were collected. The inclusion criteria for OPD
patients included passing of three or more loose/watery stools
within 24 h [23]. A total of 830 stool samples were collected from
hospitalized patients and 1000 stool samples were collected from
OPD patients. The consent of the guardian was obtained prior to
enrolling a child. The study was approved by the Institutional Eth-
ical Committee, National Institute of Cholera and Enteric Diseases.
Preliminary screening of the stool samples for the presence of RVAs
was performed using Rota-Adeno kit as per the manufacturer’s
instructions (VIKIA® Rota-Adeno, Biomerieux® sa).
2.2. Viral RNA extraction and genotyping
All the rotavirus positive samples, detected by VIKIA® Rota-
Adeno kit, were conﬁrmed for positivity by reverse transcription
and PCR to avoid a false positive result. RVA double-stranded RNA
was extracted from feces of positive samples by using a com-
mercially available RNA extraction kit (QIAamp viral RNA Mini
Kit, Qiagen GmbH, Hilden, Germany) according to the manufac-
turer’s instructions. Complementary DNA was synthesized from the
hrough December 2013 in (A) hospitalized patients with severe diarrhea (<5 years)
ion of common genotypes (G1, G2, G9 and G12).
A22 S. Mullick et al. / Vaccine 32S (2014) A20–A28
Fig. 2. Age-wise distribution of rotavirus-positive cases (0–5 years) among hospi-
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Table 1
Samples tested by EIA and positive for rotavirus by hospitalization between January
2011 and December 2013.
Hospitalized
(patient <5 years)
(%)
OPD patients (<5
years) (%)
Number of sample tested 830 1000
were deduced using the TRANSEQ software (Transeq Nucleotide
to Protein Sequence Conversion Tool, EMBL-EBI, Cambridgeshire,
F
walized and OPD patients.
xtracted viral RNA through reverse transcription in the presence of
andom hexamers. G and P genotyping was performed using VP7-
nd VP4-speciﬁc multiplex semi-nested RT-PCRs as described pre-
iously [24,25]. PCR products were puriﬁed with a QIAquick PCR
uriﬁcation kit (QiagenGmbH, Hilden, Germany).
ig. 3. Phylogenetic dendrograms based on nucleotide sequences of VP7 genes of (A) G1 a
ith  other known G1 and G2 strains, respectively. Scale bar, 0.05 substitutions per nucleNumber of rotavirus
positive samples
443 (53.4%) 475 (47.5%)
2.3. Nucleotide sequencing and phylogenetic analysis
Nucleotide sequencing was  carried out using the ABI Prism Big
Dye Terminator Cycle Sequencing Ready Reaction Kit v3.1 (Applied
Biosystems, Foster City, California, USA) in an ABI Prism 3730
Genetic Analyzer (PE Applied Biosystems, Foster City, California,
USA) as described previously [26]. Nucleotide and protein sequence
BLAST search was  performed using the National Centre for biotech-
nology Information (NCBI, National Institutes of Health, Bethesda,
MD)  Basic Local Alignment Search Tool (BLAST) server on Gen-
Bank database release 143.0 [27,28]. Pairwise sequence alignments
were performed using LALIGN software (EMBnet, Swiss Insti-
tute of Bioinformatic, Switzerland), and multiple alignments were
done with DDBJ software and CLUSTAL W.  Amino acid sequencesUK). Phylogenetic tree was  constructed using the MEGA (Molecu-
lar Evolutionary Genetics Analysis) program, version 5.2. Genetic
nd (B) G2 strains of Kolkata isolated during January 2011 through December 2013,
otide. Bootstrap values less than 70% are not shown.
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Table  2
Combinations of G and P types of rotavirus strains genotyped in (A) hospitalized and (B) OPD patients in Kolkata, India between January 2011 and December 2013.
(A) P-type G-type
G1 G2 G4 G9 G12 Untypable Total
P[4] 0 140 0 122 2 4 268
P[6]  6 6 1 0 4 0 17
P[8]  60 9 3 53 19 4 148
Untypable 4 6 0 0 0 0 10
Total  70 161 4 175 25 8 443
Percentage (%) 16.1 36.1 1.1 40.0 5.1 1.8 100
(B)  P-type G-type
G1 G2 G4 G9 G12 Untypable Total
P[4] 10 173 0 72 9 0 264
P[6]  12 0 0 0 12 0 24
P[8]  100 18 0 36 23 0 177
d
m
1
y
s
c
c
F
wUntypable 0 0 0 
Total  122 191 0 
Percentage (%) 25.5 40.3 0 
istances were calculated using maximum likelihood statistical
odel and Jones–Taylor–Thornton (JTT) substitution model (at
000 bootstrap replicates). Abbreviations used for sequence anal-
sis are: hum, human; po/por, porcine; avi, avian; mur, murine;
i/sim, simian; ovi, ovine; eq/equ, equine; bov, bovine; fel, feline;
an, canine; lap/la, lapine; lam, lamb; tu/tur, turkey; ch/chi,
hiken; cap, caprine; and out, outgroup. Lineage designation for
ig. 4. Phylogenetic dendrograms based on nucleotide sequences of VP7 genes of (A) G9 a
ith  other known G9 and G12 strains, respectively. Scale bar, 0.05 substitutions per nucl0 0 10 10
108 44 10 475
22.8 9.3 2.1 100
phylogenetic dendrograms of G1, G2, G9 and G12 strains were
based on those reported in previous studies [29–42]. Complete
nucleotide sequences of VP7 gene of the strains detected during
this study were submitted to the GenBank database under the
accession numbers: KF723263–KF723287 [KF723263–KF723268
(G1); KF723269–KF723275 (G2); KF723276–KF723283 (G9);
KF723284–KF723287 (G12)].
nd (B) G12 strains of Kolkata isolated during January 2011 through December 2013,
eotide. Bootstrap values less than 70% are not shown.
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Table 3
Amino acid identity (%) for VP7. Intragenotype similarities with Rotarix-G1,
RotaTeq-G1, RotaTeq-G2 and 116E-G9.
Amino acid identities (%) between circulating and vaccine strains: VP7
Strain name Genotype/lineage Rotarix-
A41CB052A/G1
RotaTeq-WI79-
9/G1
IDK-4226/2011 G1/II 96.9% 94.8%
IDK-5042/2013 G1/II 96.3% 94.2%
BCK-2644/2012 G1/II 95.4% 93.3%
BCK-2304/2011 G1/I 94.5% 93.3%
IDK-4418/2012 G1/I 92.6% 91.4%
BCK-2129/2011 G1/I 93.6% 92.3%
Strain name Genotype/lineage RotaTeq-SC2-9/G2
BCK-2409/2012 G2/IV 93.9%
IDK-4599/2012 G2/IV 92.6%
BCK-2601/2012 G2/IV 93.9%
BCK-2852/2013 G2/IV 91.7%
IDK-5034/2013 G2/IV 94.2%
BCK-2953/2013 G2/IV 92.6%
IDK-4292/2011 G2/IV 92.6%
Strain name Genotype/lineage 116E/AG/VACCINE/G9
BCK-2679/2012 G9/III 91.4%
BCK-2934/2013 G9/III 90.8%
IDK-4957/2012 G9/III 92.6%
IDK-5033/2013 G9/III 90.5%
BCK-2168/2011 G9/III 92.6%
IDK-4321/2011 G9/III 91.4%24 S. Mullick et al. / Vac
. Results
.1. Prevalence and epidemiology of RV in hospitalized and OPD
atients
Among the 830 fecal samples from hospitalized children and
000 samples from OPD cases, 443 (53.4%) and 475 (47.5%), respec-
ively, were positive for RVAs (Table 1).
A distinct seasonal variation in rotavirus incidence was  observed
n both hospitalized and OPD cases, with low levels of posi-
ivity (10–25%) throughout the year (November–February: Winter
eason; March–June: Summer season; July–October: Rainy sea-
on), and the peak in incidence (70–80%) during winter season
December–February) (Fig. 1A and B). Monthwise genotype varia-
ion was also analyzed though no correlation between seasonality
nd increased frequency of particular genotype was  observed
Fig. 1). In hospitalized children, G9 strains were observed at
5–55% frequency (Fig. 1A) whereas 10–45% incidence rate was
bserved in OPD children throughout the study period (Fig. 1B).
2 was observed at 10-55% frequency in hospitalized (Fig. 1A) and
t 30–55% frequency among OPD children (Fig. 1B). G1 and G12
ere observed at 10–40% and 0–20% frequency in both hospital-
zed and OPD children (Fig. 1A and B). In both the severe or mild
iarrhea cases, the maximum number of rotavirus positivity was
ound in the age group of 6–12 months followed by 12–24months
f children (Fig. 2).
.2. Rotavirus genotypes among severe and mild gastroenteritis
ases
Rotavirus genotypes were detected by multiplex semi-nested
CR method using G–P type speciﬁc primers and conﬁrmed by
ull length sequencing of the VP7 genes and partial sequencing of
he VP4 genes of strains representing different genotypes. Among
43 RVA positive samples from hospitalized children (<5 years),
9 in conjunction with P[4] and P[8], was most prevalent (40%),
ollowed by G2P[4] (39.6%). G1P[8] and G12 genotype combined
ith P[8]/P[4]/P[6] were 16.4% and 5.6%, respectively. Other lesser
ommon genotypes such as G1P[6], G2P[6], G2P[8], G4P[8] were
bserved at low frequencies (Table 2A).
Among 475 rotavirus positive cases from the OPD, the most
revalent strain was G2 in combination with P[4] (40.3%), followed
y G1P[8] and G9 combined with P[4]/P[8] genotypes at 25.5% and
2.8%, respectively. G12 strains with either P[6] or P[8] genotypes
ccurred at 9.3%. Other uncommon strains like G1P[4], G1P[6],
2P[8] were also detected at low frequency (Table 2B).
.3. Phylogenetic analysis of prevalent strains
The VP7 genes of 25 (G1 = 6, G2 = 7, G9 = 8 and G12 = 4 strains)
epresentative rotavirus strains were analyzed based on the
omplete ORF (nt 49–nt 1026; 326 amino acids). Phylogenetic den-
rograms based on nucleotide sequences were constructed and
ompared to previously reported G1, G2, G9 and G12 strains.
Kolkata G1 strains clustered in two subsets within two different
ineages. One subset of G1 strains (BCK-2129/2011, BCK-2304/2011
nd IDK-4418/2012) exhibited maximum similarities (>97%) with
hailand, India and Bangladesh G1 strains during BLAST analy-
is. Those strains remained in the same cluster within lineage I
n phylogenetic dendrogram, though these were distant from the
accine strains RotaTeq W179-9 and Rotarix A41CB052A (Fig. 3A).
he other subset of G1 strains (IDK-4226/2011, BCK-2644/2012
nd IDK-5042/2013) exhibited maximum similarities (>98%) with
trains from Australia and Thailand. These G1 strains clustered with
otarix vaccine strain within lineage II (Fig. 3A), while the VP7 (G1)
f Rotateq vaccine strain clusters in lineage III (Fig. 3A).BCK-2295/2011 G9/III 92.3%
IDK-4176/2011 G9/III 89.9%
All G2 strains (BCK-2601/2012, BCK-2409/2012, BCK-
2953/2013, BCK-2852/2013, IDK-4292/2011, IDK-4599/2012
and IDK-5034/2013) showed 98–99% nucleotide similarities with
previously reported strains from India, Nepal and Bangladesh and
clustered in lineage IV. The G2 strains from this study were distant
to RotaTeq vaccine strains in lineage II (Fig. 3B).
Phylogenetic analysis showed all G9 strains from this study
were in lineage III. Six of eight G9 strains (BCK-2168/2011, BCK-
2679/2012, BCK-2934/2013, IDK-4321/2011, IDK-4957/2012 and
IDK-5033/2013) revealed maximum identities (>96%) with previ-
ously reported human G9 strains from India and USA. These six
G9 strains were in one subcluster, whereas, IDK-4176/2011 shared
maximum homology with South African human G9 strain and BCK-
2295/2011 was  more similar with an American G9 strain. These two
strains were placed in two other subclusters of lineage III (Fig. 4A).
All the G9 strains from this study were found to be genetically dis-
tant from G9 vaccine strain 116E, which was  in lineage II (Fig. 4A).
The current G12 strains shared close nucleotide similarity
(>95%) with previously reported Indian human lineage III G12
strains. Sample IDK-5082/2013 formed distant subcluster, whereas
other three (BCK-2783/2012, BCK-2907/2013 and IDK-5095/2013)
formed another subcluster with Indian, Nepalese and Belgian G12
strains within lineage III (Fig. 4B).
3.4. Comparative analysis of VP7 protein of circulating Kolkata
RV strains and the vaccine strains
The amino acid homology of the current circulating strains was
compared to the vaccine strains. The lineage II G1 strains were sim-
ilar (92–95%) to Rotarix-G1 strain which also clustered in lineage
II (Fig. 3A), but lineage I G1 strains had 91–94% homology to either
Rotarix-G1 or RotaTeq-G1 strains (Table 3). Amino acid homol-
ogy of G2 strains with RotaTeq G2 was ∼91%, whereas Kolkata
G9 strains showed 89–92% amino acid homology with 116E-G9
vaccine strains (Table 3).
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Table 4
Alignment of the amino acid residues deﬁning the neutralization domains (designated as 7-1a, 7-1b and 7-2 [53]) of VP7 between- the G1 strains in Rotarix and RotaTeq and Kolkata G1 strains; G2 strain in RotaTeq and Kolkata
G2  strains; and G9 strain in 116E and Kolkata G9 strains. Residues that differ are highlighted.
VP7 
7-1a 7-1b 7-2
87  91  94  96  97  98 99 100   104   123   125   129   130   291   201   211   212   213  238  242  143  145  146  147  148  190  217  221  264 
Rotarix -
A41 CB0 52A/ 
G1
T T N G E W K D Q S V V D K Q N V D N T K D Q N L S M N G
RotaTeq-
WI79-9/G1  
T T N G D W K D Q S V V D K Q N V D N T K D Q S L S M N G
IDK-
4226/2011/G1 
T T N G E W K D Q S V V D K Q N V D N T K D Q N L S M N G
IDK-
5042/2013/G1 
T T N G E W K E Q S V V D K Q N V D N T K D Q N L S M N G
BCK-
264 4/2 012/G1 
T T N G E W K D Q S V V D K Q N V D N T K D Q N L S M N G
BCK-
230 4/2 011/G1 
T T S G E W K D Q N V V D R Q N V D N T K D Q N L S T N G
IDK-
441 8/2 012/G1 
T T S G E W K D Q N V V D R Q N V D N T K D Q N L S T N G
BCK-
212 9/2 011/G1 
T T S G E W K D Q N V V D R Q N V D N T K D Q N L S T N G
RotaT eq-SC2-
9/G2 
A N S D E W E N Q D T M N K Q D V S N S R D N T S D I S G
BCK-
240 9/2 012/G2 
T N S N E W E N Q D T M N K Q D V D N N R D N T S D I S G
IDK-
459 9/2 012/G2 
T N S N E W E N Q D T M N M Q D V D N N R D N T S D I S G
BCK-
260 1/2 012/G2 
T N S N E W E N Q D T M N K Q D V D N N R D N T S D I S G
BCK-
285 2/2 013/G2 
T N S N E W E N Q D T M N V Q D V D N N R D N T S D I S G
IDK-
503 4/2 013/G2 
T N S N E W E N Q D T M N K Q D V D N N R D N T S D I S G
BCK-
295 3/2 013/G2 
T N S N E W E N Q D T M N K Q D V D N N R D N T S D I S G
IDK-
429 2/2 011/G2 
T N S N E W E N Q D T M N C Q D V D N N R D N T S D I S G
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The VP7 trimer contains two structurally deﬁned antigenic
pitopes: 7-1 and 7-2. The 7-1 epitope spans the intersubunit
oundary and is further subdivided into 7-1a and 7-1b [43]. A com-
arison of residues that constitute the 7-1a, 7-1b, and 7-2 epitopes
f the Kolkata strains and the vaccine strains is presented in Table 4.
wenty nine amino acid residues of this antigenic epitope of the VP7
roteins of circulating G1, G2, and G9 RVA strains were compared
ith the Rotarix-G1, RotaTeq-G1, RotaTeq-G2, and 116E-G9 vac-
ine strains. Kolkata G1 strains showed mismatches in 94, 100, 123,
91 and 217 positions in 7-1a and 7-2 domains with Rotarix-G1and
otaTeq-G1strains. Kolkata G2 strains also showed mismatches in
 positions, 87, 291, 213 and 242 in respect to RotaTeq-G2 strains.
hen VP7 protein of G9 strains were compared with 116E-G9 vac-
ine strain, it revealed that circulating lineage III G9 strains also
iffer from 116E strain within antigenic domain at 87, 94, 100, 291,
42, 145 and 221 positions (Table 4).
. Discussion
In low income countries of Asia (India, Bangladesh, Pakistan,
ietnam, China) and Africa, high prevalence (30–40%) of RV has
een reported among hospitalized children [17,44–49]. In this
tudy, the incidence was higher in hospitalized children (53.4%) and
ut-patients (47.5%) than previous reports. The children seeking
reatment in outpatient departments may  constitute a major source
or dissemination of virus. Unlike developed countries where one
r two genotypes predominate in a season [54,55], a large number
f genotypes was observed (G9, G2, G1, G12) at >15% frequency
n Kolkata. This agrees with the previous reports from India and
angladesh [17,44]. Although not demonstrated so far, emergence
f new strains, which contributes to genetic diversity, may  be one
ause of lower vaccine efﬁcacy in developing countries. Selective
ressure resulting from population immunity may  drive emer-
ence of strains able to evade vaccine immunity [13].
Moreover for improving efﬁcacy, mass vaccination of children
hrough national immunization program is required, whereas in
ountries like India, currently only a small proportion of children
re vaccinated. Considering the socio-economic structure, high
ost of vaccines and the large diversity of strains in low income
ountries, successful implementation of RV vaccines is still an
nfulﬁlled goal [17,25,50]. Thus to fulﬁll the lacunae of disease
ontrol by vaccination, continuous surveillance for RV is required
o monitor incidence, circulating genotypes, emergence of new
eassortant strains in population, which will also help in effective
isease management and prevention of large scale outbreaks. In
ddition knowledge of currently circulating strains is needed prior
o mass vaccination, for comparison and evaluation during post
accination studies.
As Kolkata has a tropical climate, seasonality of rotavirus infec-
ion (Fig. 1) was found to be similar to that reported from some
egions of Asian countries where low level of RV is detected
hroughout the year, but a peak is observed predominantly dur-
ng winters [17,41,48,51,52]. In this study, most of the rotavirus
ositive children were from 6 to 12 months age groups (Fig. 2),
uggesting that the post breast feeding age group is more prone to
otavirus infection.
In this study, G9 was the most common strain (40%) responsi-
le for severe diarrhea related hospitalizations (Table 2). Previous
tudies during 2003–2009, showed that, in the eastern part of India,
1 (>50%) and G2 strains (∼23–33%) were dominant, whereas G9
2–10%) and G12 (8–17%) strains occurred at lower frequencies
19–21], and similar trends were reported in western, northern
nd southern parts of India [17,18,20–22]. During the current study
eriod, G9 and G2 strains predominated, causing 75% and 62% of all
V infections among hospitalized and OPD cases, respectively. G12S (2014) A20–A28
genotypes were still observed at 16–25% (Table 2). Previously avail-
able two rotavirus vaccines have shown high effectiveness against
several strains not in the vaccine including G9 and G12 in countries
like USA [13,15], suggesting there is a heterotypic protection. Still in
countries like India, where genotypic diversity is very high, strains
like G9 and G12 should be included in the vaccine. The high preva-
lence of G9 observed in this study suggests that it may be valuable
to have a vaccine that includes serotype G9 such as strain 116E, that
is currently in the pipeline.
Nucleotide sequence based homology analysis with respect to
previously reported G9 strains revealed close similarity of Kolkata
G9 strains to previously reported lineage III strains from the Indian
subcontinent (India, Bangladesh and Nepal) (Fig. 4A). The currently
licensed vaccine from India (Rotavac) 116E, has G9P[11] genotype
and the G9 strains from Kolkata showed low amino acid homology
(89.9–92.6%) with 116E vaccine strain (Table 3), but the vaccine
strain was derived from a non-symptomatic neonatal infection and
was adapted to cell culture several years ago [10–12]. Similarly the
circulating lineage II G1 and lineage IV G2 strains were also found to
be distant from the current vaccine strains (Rotarix and RotaTeq).
VP7 antigenic domain of Kolkata G1and G2 strains also revealed
mismatches with that of vaccine strains (Table 4). Knowledge of
currently circulating strains is needed prior to vaccination, for com-
parison and evaluation during post vaccination studies. Fluctuation
of genotypes due to accumulation of point mutations (genetic drift)
in the antigenic domain of VP7 gene is one potential reason for
changes in circulating strains [53,54]. The amino acid analysis of the
VP7 antigenic domains compared with vaccine strain was  not done
earlier in this region. The antigenic variation observed between cir-
culating strains and vaccine strains may  inﬂuence vaccine efﬁcacy
in these settings. Thus it will be important to monitor the impact
of vaccine pressure on antigenic variation to determine whether
particular changes will alter long-term vaccine effectiveness over
time.
In addition to documenting the differences between circulating
and vaccine strains, the study highlights the very high prevalence
of RV in children reporting with severe diarrhea or milder disease.
The circulating genotypes have changed over the time, with G9
and G2 genotypes being most predominant during 2011–2013. The
study demonstrates the high burden of RV gastroenteritis, provid-
ing strong support to introduction of RV vaccines in the regions,
where burden is high.
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